Opiant Pharmaceuticals and Aptar Pharma Expand Long-Term Collaboration for the Manufacture of Unidose Nasal Spray for OPNT003, Nasal Nalmefene
June 08 2022 - 4:05PM
Opiant Pharmaceuticals, Inc. (Opiant) (NASDAQ: OPNT) today
announced a capacity investment agreement with Aptar Pharma
(Aptar), a leading provider of drug delivery systems, to
expand production of Aptar’s nasal Unidose device, which will be
used in the production of commercial supply of OPNT003, nasal
nalmefene.
The agreement includes an investment by Opiant of €2 million
(approximately $2.1 million) and a commitment by Aptar to install
and maintain equipment in support of increased future production of
its Unidose device to meet the potential commercial demand for
OPNT003, nasal nalmefene.
“This capacity investment with Aptar demonstrates Opiant’s
commitment to ensure adequate supply of OPNT003, nasal nalmefene,
to communities and emergency responders as quickly as possible, if
approved,” said Roger Crystal, M.D., President and Chief
Executive Officer of Opiant.
Opiant has initiated rolling submission of a New Drug
Application to the U.S Food and Drug Administration (FDA), for
OPNT003, nasal nalmefene, for the treatment of opioid overdose,
using the 505(b)(2) pathway. It intends to complete its application
in the second half of 2022. Opiant was granted Fast Track
Designation in November 2021.
About Opiant Pharmaceuticals,
Inc. Opiant Pharmaceuticals, Inc., the company that
developed NARCAN® Nasal Spray, is building a
leading franchise of new medicines to combat addictions
and drug overdose. For more information
visit: www.opiant.com.
Forward-Looking StatementsThis press release
contains forward-looking statements. These statements relate to
future events or our future financial performance and involve known
and unknown risks, uncertainties and other factors that may cause
our actual results, levels of activity, performance or achievements
to be materially different from any future results, levels of
activity, performance or achievements expressed, implied or
inferred by these forward-looking statements, and among other
things, completion of the NDA filing in the second half of 2022. In
some cases, you can identify forward-looking statements by
terminology such as "may," "will," "should," "could," "would,"
"expects," "plans," "intends," "anticipates," "believes,"
"estimates," "predicts," "projects," "potential," or "continue" or
the negative of such terms and other comparable terminology. These
statements are only predictions based on our current expectations
and projections about future events. You should not place undue
reliance on these statements. Actual events or results may differ
materially. In evaluating these statements, you should specifically
consider various factors. Additional factors that could materially
affect actual results can be found in our Form 10-K for the year
ended December 31, 2021 and our Form 10-Q for the quarter
ended March 31,2022, filed with the Securities and Exchange
Commission on March 4, 2022 and May 10, 2022,
respectively, including under the caption titled "Risk Factors."
These and other factors may cause our actual results to
differ materially from any forward-looking statement. We undertake
no obligation to update any of the forward-looking statements after
the date of this press release to conform those statements to
reflect the occurrence of unanticipated events, except as required
by applicable law.
For Media and Investor Inquiries:Ben Atkins, Opiant(310)
598-5410batkins@opiant.com
Opiant Pharmaceuticals (NASDAQ:OPNT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Opiant Pharmaceuticals (NASDAQ:OPNT)
Historical Stock Chart
From Sep 2023 to Sep 2024